Korodin (Camphor) for Circulatory Support and Associated Symptoms

---

Quick Facts

• Supports circulatory regulation.
• May address symptoms associated with low blood pressure (hypotension).
• Assists in the management of dizziness, particularly upon standing up from a lying or seated position (orthostatic circulatory disorders).

---

Korodin, which contains the substance camphor alongside an extract of hawthorn fruit, is generally utilized to support the maintenance of circulatory function.

Its therapeutic domain involves providing relief for symptoms that can present as a result of low blood pressure, medically termed hypotension. This includes the management of light-headedness or dizziness, which may occur when an individual shifts position, such as when standing after a period of rest or prolonged sitting (orthostatic circulatory disorders).

The preparation contributes to the symptomatic treatment of these discomforts by acting on the cardiovascular system to help stabilize blood pressure. This combination of active ingredients is traditionally used for circulatory regulation disorders and related hypotensive complaints.

This medication is specifically intended to assist in the alleviation of complaints associated with poor circulation and is not for use in conditions beyond its intended scope.

Eligibility Scope

The primary population permitted to use Korodin Herz-Kreislauf-Tropfen is adults aged 18 years and older, provided no specific contraindications apply. The regulatory label defines strict exclusions and limitations for several population groups.

Populations for whom use is contraindicated:

• Infants and small children up to 2 years: Absolutely prohibited due to the risk of camphor-induced laryngospasm.
• Patients with Hypersensitivity: Prohibited for individuals allergic to D-Camphor, Hawthorn, or other excipients.
• Respiratory Conditions: Contraindicated in patients with Bronchial Asthma or other respiratory diseases involving marked airway hypersensitivity.

Populations for whom use is restricted or not recommended:

• Children and Adolescents (Under 18 years): Not recommended due to a documented lack of safety and efficacy data and the preparation’s 60% alcohol content.
• Pregnancy and Lactation: Not recommended for pregnant women (due to insufficient data) and should not be taken by breastfeeding women (risk to infant cannot be excluded).
• Comorbidity Limitations: The high ethanol content requires special consideration for patients with alcoholism, pre-existing liver disease, or epilepsy.

Interactions with other medicines and products

The official regulatory profile for Korodin, a fixed combination of D-Camphor and Crataegus (Hawthorn) extract, addresses two primary areas of interaction: pharmacodynamic effects and substance-based restrictions.

Pharmacodynamic Interaction Cautions

The Crataegus (Hawthorn) extract component, based on its established regulatory monograph profile, carries a caution regarding co-administration with certain prescription medicines due to the potential for additive effects on the cardiovascular system. This is classified as a Pharmacodynamic Potentiation interaction.

• Cardiac Glycosides: A caution is advised when co-administered with medicines such as Digoxin due to the potential for an additive effect on myocardial function.
• Blood Pressure Medications: Caution is also warranted for combination with Antihypertensives due to the possibility of additive effects on circulatory regulation.

Substance-Related Constraints

The formulation contains a high concentration of Ethanol (60% V/V), which constitutes a mandatory Substance Restriction consideration outlined in the regulatory documentation. This constraint is not a drug–drug interaction but a factor related to the formulation's composition.

• Vulnerable Populations: Regulatory labeling requires specific consideration of this ethanol content for patients with liver disease or epilepsy, and for use in children and adolescents.

Rapid Sympathetic Reflex for Peripheral Resistance

The core mechanistic action begins with D-Camphor serving as an activator of peripheral sensory receptors, notably TRP ion channels. This initiates a fast, reflexive signal to the brainstem's cardiorespiratory centers, rapidly increasing sympathetic nervous system outflow. This pathway produces widespread vasoconstriction, resulting in an elevation of Total Peripheral Resistance (TPR) and the rapid modulation of systemic perfusion pressure.

---

Crataegus: Enzyme Modulation and Myocardial Contractility

The sustaining component of the effect is achieved by the Crataegus extract, which acts directly on the heart muscle. Its active constituents modulate cardiac enzymes by mildly inhibiting the Na^+/ K^+- ATPase pump and cAMP phosphodiesterase ( cAMP-PDE). This molecular interaction enhances the availability of intracellular calcium ( Ca^2+), leading to a positive inotropic effect—an increase in the force and efficiency of myocardial contraction.

---

Synergistic Dual-Action for Circulatory Modulation

The drug's overall effect results from the pharmacodynamic synergy of its two active components. D-Camphor provides the quick, neurologically driven pressure modulation (TPR increase), while Crataegus is sustaining the resultant physiological effects by increasing the force and output of myocardial contraction (stroke volume). This dual modulation of both the vascular system and cardiac output results in the simultaneous adjustment of systemic resistance and cardiac performance.

Korodin Herz-Kreislauf-Tropfen is administered solely via the oral route as a concentrated liquid drop solution. The general principle of usage follows two distinct patterns: routine support and acute episode management. The dosing for adults for ongoing support is typically 10 drops, three times daily. A higher single dose of up to 25 drops may be used, though this should not exceed a total daily dose of three times daily.

For acute episodes involving sudden circulatory weakness, an intermittent regimen consists of 5 to 10 drops, which may be repeated every 15 minutes until relief is achieved. The required administration technique is non-standard. The drops must be placed undiluted directly onto the tongue or dripped onto a piece of sugar or bread to be slowly dissolved in the mouth. A mandatory restriction stipulates that the dose must not be taken with water, and no fluid intake is permitted for 5 minutes immediately preceding and following administration.

The required frequency is independent of the meal schedule. Regarding duration, the application is not limited in time, which supports its potential use as part of a long-term therapeutic plan. Furthermore, use is not recommended for children and adolescents under 18 years and is absolutely prohibited for children under 2 years of age.

Korodin (Camphor): Recent Clinical Evidence

Evidence for Use in Hypotension and Circulatory Disorders

Research examined this combination in patients with low blood pressure (hypotension) and associated circulatory problems. Systematic reviews and individual randomized controlled trials (RCTs) have been the primary study types applied in studies examining patient-reported experiences related to these conditions associated with acute or disruptive episodes. The studies monitored measurements of change in systolic and diastolic blood pressure across the study groups. Research explored short-term symptom changes in conditions involving temporary physiological imbalance and reported measurements related to blood pressure patterns observed during postural changes.

Types of Outcomes Studied in Trials

Research has primarily monitored outcomes related to systemic or functional imbalance, with key measures focusing on physical parameters like blood pressure and heart rate. Studies also explored outcomes related to physical discomfort and daily functioning, which were captured using patient-reported outcomes describing perceived discomfort. Furthermore, a number of trials explored attentional and cognitive performance using standardized psychological testing. Studies monitored changes measured during the study period for both physiological markers and certain functional measures.

Long-Term Evidence and Follow-up Durations

Studies observed responses over defined time intervals, and follow-up durations were limited in much of the published research. Trials have explored short-term symptom changes, ranging from measurements taken within minutes after a single administration to those taken over a period of one week of repeated administration. Research provides insight into short-term changes, but long-term effects are not fully established, and there is limited information for long-term outcomes in the scientific literature.

Evidence in Specific Groups of Patients

Research has explored the combination in different age cohorts. Studies were conducted during periods of increased symptom activity in adolescents with low blood pressure, adults with chronic hypotension, and elderly patients (aged 50 years and older). Findings describe group patterns related to these specific populations. However, data for certain other demographic or health-defined groups remain insufficient, meaning that results apply only to the populations studied in the existing trials.

Evidence Quality and Key Research Gaps

The evidence quality varies across studies, with systematic reviews providing a structured assessment of the overall research landscape. These assessments clarify that the overall quantity of the evidence base is limited, which contributes to the broader evidence landscape but indicates that certainty remains low in some areas. Research is ongoing, but the specific duration of use related to the observed physiological patterns is not fully established. Additionally, the comparative evidence is lacking for comparisons against other established therapies in the current body of published research.

Common questions about Korodin (Camphor) (FAQ)

---

Q: Is Korodin considered a purely herbal medicine?

A: Official documents classify Korodin as both a Phytotherapy and an Antihypotensive Agent. It is defined as a fixed combination product. The formulation contains two distinct active ingredients: the plant-derived Crataegus (Hawthorn) extract and D-Camphor, which is the naturally occurring isomer.

---

Q: How quickly do the Korodin drops generally start to show an effect?

A: According to the medicine's documented mechanism, the D-Camphor component initiates a rapid response to the brain. This process is described as increasing sympathetic nervous system outflow, contributing to quick, neurologically driven pressure modulation.

---

Q: Is the camphor in Korodin the same type used in topical chest rubs?

A: The active ingredient in the drops is specified in the regulatory information as D-Camphor. This is the naturally occurring isomer of camphor. This designation identifies the specific chemical form used in the oral medicine.

---

Q: What does 'orthostatic circulatory disorder' mean in accessible, non-medical terms?

A: This term refers to a circulatory condition related to a temporary physiological imbalance, often experienced as dizziness or lightheadedness when changing posture (like standing up). The medicine is generally indicated for circulatory disorders that cause these symptoms, and its purpose is related to blood pressure stabilization.

---

Q: Does the medicine contain any other ingredients besides camphor and hawthorn extract?

A: Yes, the official composition documents indicate that the active ingredients are dissolved in a liquid base of Ethanol. This excipient is present in a high concentration, typically specified as 60% V/V.

---

Q: What should a person do if they notice palpitations after taking the drops?

A: Official safety information lists palpitations as a reported adverse reaction of Frequency Not Known (incidence cannot be estimated from available data) in the product profile.

---

Q: How does the medicine’s mechanism differ from that of a standard blood pressure medication?

A: The medicine’s effect is based on a synergistic dual-action approach. The D-Camphor component is described as contributing to a quick, neurologically driven increase in Total Peripheral Resistance (vascular action), and Crataegus is described as supporting the force and efficiency of myocardial contraction (cardiac action).

---

Q: What are the signs that a person might have used an excessive amount of the drops?

A: Official safety information notes that the D-Camphor component is associated with a risk of Central Nervous System (CNS) and Gastrointestinal (GI) symptoms if an excessive amount is used. Documented adverse reactions in this category may include excitement, anxiety, vomiting, and in severe cases, seizures.

How to Store and Dispose of Korodin (Camphor) Drops

The official labeling for Korodin Herz-Kreislauf-Tropfen defines specific requirements for storage and stability.

---

Storage Requirements

Storage Condition Type	Requirement
Temperature	No special storage conditions are required, allowing for ambient temperature storage.
Light/Moisture	No explicit protection from light or moisture is specified.
Child Safety	The medicine must be stored out of the reach of children.

---

⏳ Stability and Disposal

The drops remain stable until the printed expiry date even after the bottle has been opened. The product must not be used after the date marked on the label and carton.

Official regulatory documents do not provide explicit instructions for the disposal of unused or expired Korodin. Discarding the product should follow general guidelines for household medicine disposal.